IDEA Innovative Drug European Associates

IDEA (Innovative Drug European Associates) was a German biopharmaceutical company specializing in the development of non-invasive drug delivery systems. The company's core technology, Transfersome, utilized highly deformable lipid vesicles to transport therapeutic agents across the skin barrier. Its lead product, Diractin (a topical ketoprofen gel), received marketing authorization from the European Medicines Agency in 2007 for the treatment of osteoarthritis pain. Despite this regulatory success, the company faced significant financial challenges and filed for insolvency in 2010. IDEA's research also included transdermal formulations for insulin and interferon, aiming to provide needle-free alternatives for chronic conditions.